Rhenman & Partners Asset Management AB Reduces Stock Holdings in Stoke Therapeutics, Inc. $STOK

Posted by Stanley Muller on Jun 13th, 2026

Rhenman & Partners Asset Management AB decreased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 13.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,000 shares of the company’s stock after selling 34,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Stoke Therapeutics were worth $6,856,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Harbour Investments Inc. lifted its stake in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC purchased a new position in Stoke Therapeutics in the third quarter valued at approximately $41,000. BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after purchasing an additional 5,427 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on STOK. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Wolfe Research began coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price on the stock. Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Finally, Needham & Company LLC boosted their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $41.83.

View Our Latest Research Report on Stoke Therapeutics

Insider Activity

In other news, insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $209,539.24. Following the transaction, the insider owned 40,798 shares of the company’s stock, valued at approximately $1,278,609.32. This represents a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88. Following the completion of the transaction, the chief financial officer directly owned 10,172 shares in the company, valued at approximately $318,790.48. The trade was a 18.97% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 33,291 shares of company stock worth $1,064,065. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $29.82 on Friday. The company’s fifty day simple moving average is $32.24 and its two-hundred day simple moving average is $32.36. Stoke Therapeutics, Inc. has a 1 year low of $11.17 and a 1 year high of $40.22. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -10.61 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The business had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. Equities research analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.

Stoke Therapeutics Profile

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.